Josep Maria Piulats

13PUBLICATIONS
104CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyTissue engineeringCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 28, 2025
Comment on: "Tebentafusp Versus Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma: An E‑Value Sensitivity Analysis Assessing Effect of Unmeasured Confounders on Observational Associations".

Claire Watkins, Luis Del Carpio, Josep M Piulats

|Sep 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Takami Sato, Marcus O Butler, Sophie Piperno-Neumann

|Mar 11, 2025
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer.

Esra Güç, Agatha Treveil, Emma Leach

|Jun 24, 2024
Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma.

Laura Lorenzo-Sanz, Marta Lopez-Cerda, Victoria da Silva-Diz

|Mar 21, 2024
A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.

Neeraj Agarwal, Daniel Castellano, Teresa Alonso-Gordoa

|May 22, 2023
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.

Luis P Del Carpio, María Asunción Algarra, Aida Sabaté-Llobera

Pageof 3

Frequent Collaborators

2 joint publications

Joseph J Sacco

2 joint publications

Xavier Matias-Guiu

2 joint publications

Sandra García-Mulero

2 joint publications

Daniel Lorenzo